Marc Wilson Crinetics Pharmaceuticals, Inc. (CRNX) insider trading activity

CRNX Quotes by TradingView

Marc Wilson is CFO of Crinetics Pharmaceuticals, Inc.. Currently has a direct ownership of 111,092 shares of CRNX, which is worth approximately $6.3 Million. The most recent transaction as insider was on Sep 26, 2024, when has been sold 25,000 shares (Common Stock) at a price of $51.11 per share, resulting in proceeds of $1,277,750. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 111K
0% 3M change
16.2% 12M change
Total Value Held $6.3 Million

Marc Wilson Transaction History

Date Transaction Value Shares Traded Shares Held Form
Sep 26 2024
SELL
Open market or private sale
$1,277,750 $51.11 p/Share
25,000 Reduced 18.37%
111,092 Common Stock
Sep 26 2024
BUY
Exercise of conversion of derivative security
$382,250 $15.29 p/Share
25,000 Added 15.52%
136,092 Common Stock
Jul 25 2024
SELL
Open market or private sale
$1,026,737 $53.88 p/Share
19,056 Reduced 14.64%
111,092 Common Stock
Jul 25 2024
BUY
Exercise of conversion of derivative security
$176,839 $9.28 p/Share
19,056 Added 12.77%
130,148 Common Stock
Jul 15 2024
SELL
Open market or private sale
$1,375,000 $55.0 p/Share
25,000 Reduced 18.37%
111,092 Common Stock
Jul 15 2024
BUY
Exercise of conversion of derivative security
$500,500 $20.02 p/Share
25,000 Added 15.52%
136,092 Common Stock
Jun 28 2024
SELL
Open market or private sale
$1,401,145 $43.61 p/Share
32,129 Reduced 22.43%
111,092 Common Stock
Jun 28 2024
BUY
Exercise of conversion of derivative security
$298,157 $9.28 p/Share
32,129 Added 18.32%
143,221 Common Stock
Mar 19 2024
SELL
Open market or private sale
$297,881 $42.91 p/Share
6,942 Reduced 5.9%
110,630 Common Stock
Mar 18 2024
SELL
Payment of exercise price or tax liability
$151,911 $38.14 p/Share
3,983 Reduced 3.28%
117,572 Common Stock
Mar 04 2024
BUY
Grant, award, or other acquisition
-
25,500 Added 17.34%
121,555 Common Stock
Jan 02 2024
SELL
Open market or private sale
$354,700 $35.47 p/Share
10,000 Reduced 9.43%
96,055 Common Stock
Jan 02 2024
BUY
Exercise of conversion of derivative security
$92,800 $9.28 p/Share
10,000 Added 8.62%
106,055 Common Stock
Nov 01 2023
SELL
Open market or private sale
$287,500 $28.75 p/Share
10,000 Reduced 9.47%
95,601 Common Stock
Nov 01 2023
BUY
Exercise of conversion of derivative security
$92,800 $9.28 p/Share
10,000 Added 8.65%
105,601 Common Stock
Jun 20 2023
SELL
Open market or private sale
$617,203 $19.96 p/Share
30,922 Reduced 24.53%
95,158 Common Stock
Jun 20 2023
BUY
Exercise of conversion of derivative security
$185,600 $9.28 p/Share
20,000 Added 14.8%
115,158 Common Stock
Mar 16 2023
SELL
Payment of exercise price or tax liability
$28,521 $17.12 p/Share
1,666 Reduced 1.55%
106,080 Common Stock
Mar 01 2023
BUY
Grant, award, or other acquisition
-
24,200 Added 18.34%
107,746 Common Stock
Feb 28 2022
BUY
Grant, award, or other acquisition
-
19,500 Added 19.28%
81,618 Common Stock
MW

Marc Wilson

CFO
San Diego, CA

Track Institutional and Insider Activities on CRNX

Follow Crinetics Pharmaceuticals, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells CRNX shares.

Notify only if

Insider Trading

Get notified when an Crinetics Pharmaceuticals, Inc. insider buys or sells CRNX shares.

Notify only if

News

Receive news related to Crinetics Pharmaceuticals, Inc.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on CRNX